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Abstract
Background: Health decision makers need to know the impact of the development of a new intervention on the
public health and health care costs so that they can plan for economic and financial objectives. The aim of this
study was to determine the budget impact of adding Haemophilus influenzae type b (Hib) as a part of a
Pentavalent vaccine (Hib-HBV-DTP) to the national childhood immunization schedule of Iran.
Methods: An excel-based model was developed to determine the costs of including the Pentavalent vaccine in the
national immunization program (NIP), comparing the present schedule with the previous one (including separate
DTP and hepatitis B vaccines). The total annual costs included the cost of vaccination (the vaccine and syringe) and
the cost of Hib treatment. The health outcome was the estimated annual cases of the diseases. The net budget impact
was the difference in the total annual cost between the two schedules. Uncertainty about the vaccine effectiveness,
vaccination coverage, cost of the vaccine, and cost of the diseases were handled through scenario analysis.
Results: The total cost of vaccination during 5 years was $18,060,463 in the previous program and $67,774,786 in the
present program. Inclusion of the Pentavalent vaccine would increase the vaccination cost about $49 million, but
would save approximately $6 million in the healthcare costs due to reduction of disease cases and treatment costs.
The introduction of the Pentavalent vaccine resulted in a net increase in the healthcare budget expenditure across all
scenarios from $43.4 million to $50.7 million.
Conclusions: The results of this study showed that the inclusion of the Pentavalent vaccine in the NIP of Iran had a
significant impact on the health care budget and increased the financial burden on the government.
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Background
Considering the increasing costs of the health sector in
all countries of the world and the limited budget in this
area, it is necessary to use the resources efficiently. Due
to the lack of uniformity in terms of health and financial
resources in different countries, decision-makers should
make decisions based on the existing conditions and the
needs of their countries using evidence-based measures.
Economic assessment in the context of each country is
an example of evidence. Economic evaluation studies are
valuable tools to demonstrate ways to use limited re-
sources efficiently [1].
Based on the need, especially when a new technology
emerges which is often expensive, economic evaluation
studies, including cost-effectiveness studies and budget
impact analysis (BIA) are designed and implemented
and the results of these studies will be available to
decision makers in the health sector. While cost-
effectiveness studies demonstrate the value of an
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intervention and help to assign a priority to interventions,
budget impact analysis helps to assess the affordability
and sustainability of the interventions [1, 2]. Among these
technologies are new and expensive vaccines.
Haemophilus influenzae type b (Hib) plays an import-
ant role in the mortality and morbidity of children under
5 years old all around the world. In 2000, Hib caused
8.13 million serious illnesses worldwide and 371000
deaths in children aged 1–59 months [3].
The most important clinical manifestations of Hib are
meningitis, pneumonia, and other non-meningitis-non-
pneumonia (NMNP) diseases like septicemia, orbital cel-
lulitis, septic arthritis, osteomyelitis, and sinusitis [4].
The first vaccine against Hib was produced in early
1970s and the vaccines against Hib are currently avail-
able in two forms on the market, monovalent or in com-
bination with other vaccines [5].
Some advantages of combined vaccines are reducing
the number of visits and injections, reducing the patient
discomfort, increasing compliance, reducing operational
costs, and optimizing preventive measures. The com-
bined vaccine including DTP-HB-HIB has shown proper
immunogenicity in clinical trials with similar adverse
events to the separate vaccines [6, 7].
One of the oldest and most successful public health
interventions in Iran is the immunization program
which has resulted in the control, elimination, or
eradication of infectious diseases suggested by the
World Health Organization (WHO). Iran accepted the
Expanded Program of Immunization (EPI) in 1978
and implemented the EPI since 1984. Vaccination
against Diphteria, Tetanus, and Pertusis has been car-
ried out since then, and Hepatitis B vaccine was
added to the national program in 1993. The national
immunization technical advisory group (NITAG) was
established in 1982 prior to the implementation of
the EPI. The NITAG provides evidence based advice
to the Ministry of Health on the national immunization
policy and plays an important role in the decision making
process. The evidence includes the disease burden and
cost-effectiveness studies [8, 9]. To determine whether
Hib vaccination should be included in the immunization
program, two studies were conducted in Iran. In the first
study conducted under the supervision of the WHO, it
was found that the annual incidence rate of Hib men-
ingitis was 8.5/100,000 in children under 5 years old
(unpublished study).
In the second study, the specimens obtained from the
oropharynx of 1000 children in Tehran were cultured
from October 2005 to March 2006. The results demon-
strated that the prevalence of Hib carriers was 7.6% [10].
Before adoption of this new vaccine, a cost-effectiveness
study was done which concluded vaccination against
Hib was cost-effective in the context of Iran [11].
Based on these studies and other factors like WHO
recommendations, the Iranian Ministry of Health added
the Hib vaccine as a Pentavalent vaccine in combination
with DTP (Diphteria-Tetanus-Pertusis) and Hepatitis B
to the immunization program from November 2014 in-
stead of separate Hepatitis B and DTP vaccines. This
vaccine is available to all children who are born in Iran
and is administered in 3 doses at 2, 4, and 6 months of
age.
Health decision makers need to know the impact of
new vaccines on the public health and health care costs
so that they can plan for economic and financial objec-
tives. Financial sustainability for immunization programs
requires resources that are available at the right time to
achieve the desired health goals ultimately. Lack of or
delay in the planned budget, limits the population cov-
ered in the immunization program; therefore, a suffi-
cient, timely, and reliable budget supply is very vital.
BIA studies predict funds needed for vaccine supply,
help with proper budget planning, and give clear visibil-
ity to decision makers and health planners.
The aim of this study was to determine the budget im-
pact of adding the Pentavalent vaccine (HIB-HBV-DTP)
to the national childhood immunization schedule in
Iran. In this regard, we estimated the annual health ben-
efits of the vaccine and then estimated the impact of
introducing the Pentavalent vaccine to the national
childhood immunization program on the health budget.
Methods
Study design
Since we previously had DTP and Hepatitis B vaccines
in the national immunization schedule, we only consid-
ered the diseases caused by Hib in this study.
The health benefit of the vaccination was the differ-
ence in the annual disease cases between the two
immunization schedules (with and without the Hib
vaccine). To assess the impact of the Pentavalent vaccine
on the health budget, we estimated the annual direct
medical costs of the treatment of Hib diseases in the
previous immunization schedule (without the Pentavalent)
and the present schedule (including Pentavalent), so the
comparison arm was the previous schedule. The perspec-
tive of the study was the government and governmental
and quasi-governmental insurance organizations. Total
annual costs were the treatment costs of Hib diseases and
vaccination costs. Discounting was not applied to the
budget impact analysis because the budget holder is inter-
ested in real financial streams over time and it is intended
as a year-by-year projection to guide budgetary planning
[1]. We used the Microsoft Excel® 2013 for all the
calculations.
The time horizon was 5 years from November 2014 to
November 2019. The study population was all the
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children born in this period and the first birth cohort
was the children that had their first vaccine dose in
November 2014. The health outcomes were the esti-
mated annual cases of meningitis, pneumonia, and septi-
cemia as NMNP diseases caused by Hib and also the
complications of meningitis, including seizure disorders,
hearing problems, deafness, and cerebral palsy.
According to the official exchange price in 2015–2016,
the mean price of the $1 was 29721 Iranian Rials [12].
Vaccination costs
To estimate the vaccination costs, we considered the costs
of the vaccine and the syringe. Since the Pentavalent vac-
cine replaced the DTP vaccine in the schedule (at 2, 4 and
6 months of age), we did not include the logistic and
personnel costs because they were the same in both pro-
grams. We did not consider the adverse effects of the vac-
cine because in two systematic reviews on the efficacy and
safety of Hib conjugate vaccines including both monova-
lent and combined vaccines, no serious adverse effects
were reported in any of the included trials [13, 14].
Moreover, after consultation with experts in the Iranian
Ministry of Health, we assumed the adverse effects would
be similar to the DTP vaccine (injection site reactions and
a mild fever) [15].




 number of doses=child
 predicted wastage factor
Table 1 shows the information of the vaccines in the
two schedules. In addition, the cost of each syringe was
assumed $0.047 and the number of needed syringes per
child was considered 5 in the previous and 3 in the
present schedule. The information about the costs of the
vaccine and syringe and the estimated wastage rate of
each vaccine (Pentavalent, DTP and Hepatitis B) was ob-
tained from the Iranian Ministry of Health. The vaccin-
ation coverage was obtained from a national survey and
considered similar to the DTP vaccine coverage in Iran
with different rates in urban and rural districts [16].
We obtained the target population data from the Stat-
istical center of Iran [17] and estimated the birth cohort
based on the population growth rate announced by the
same center for the next four years.
The policy of the Ministry of Health to reduce the vac-
cine wastage rate is to use single dose Pentavalent vac-
cines in the rural districts and multi dose Pentavalent
vaccines in the urban districts of the country. We con-
sidered the costs of these two kinds of vaccines and the
different populations in urban and rural districts of Iran
in our calculations.
Cost estimates (direct medical costs)
To obtain the direct medical costs of the treatment of
meningitis, pneumonia, septicemia, seizure disorders,
and cerebral palsy due to meningitis, we used the mean
costs of hospitalization for children less than 5 years of
age from two public hospitals in Tehran (Markaz Tebi
and Rasoul Akram Hospitals) from March 2015 to
March 2016. To estimate the medical costs of hearing loss
and deafness (including cochlear implantation), we used
the experts’ opinions (Audiometrists & otolaryngologists).
For patients who had seizure during their hospitalization
with a permanent sequelae on brain images, we added a
cost of two years of outpatient seizure therapy based on
the expert opinion.
The Ministry of Health (government) is responsible
for providing free vaccines for all the children in the
country and there are several governmental and quasi-
governmental (Social Security Insurance, Iran Health
Insurance, and Armed Forces Medical Services Insurance)
insurance organizations in Iran [18]. Ninety-seven percent
of the Iranian population has health insurance and 90%
has governmental and quasi-governmental insurance, and
the health insurance contribution for hospitalized patients
is 90% [19], so the perspective of this study was the gov-
ernment and governmental and quasi-governmental in-
surance organizations [20, 21]. The tariffs for drugs and
medical services were considered the same in these insur-
ance organizations.
Disease burden
Based on a study conducted under the supervision of
the WHO, which has not been published yet, the annual













Pentavalent (single dose) 2 2.85 2.91 3 8.73 96.47
Pentavalent (multi dose) 10 2.34 2.60 3 7.8 96.54
HB 15 0.33 0.39 3 1.17 96.20
DTP 20 0.31 0.38 3 1.14 96.51
DTP Diphteria, Tetanus, Pertusis, HB Hepatitis B, FIC Fully Immunized Child, USD United States Dollars
Teimouri et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:1 Page 3 of 8
incidence rate of Hib meningitis, before the vaccination
era was 8.5/100,000 in children under 5 years in Iran.
Based on the CCDC information, we assumed 80% of
meningitis cases were children under 1 year of age and
estimated Hib meningitis cases in the five-year period of
the study.
For pneumonia cases, according to the results of rapid
Hib disease assessment method proposed by the WHO,
there are 5 cases of Hib pneumonia for each case of Hib
meningitis [3].
Since other Hib diseases are relatively rare, these are
grouped in one syndrome as NMNP Hib diseases and
the rates between cases of NMNP and meningitis as-
sumed 0.35 [4]. For assessing the consequences of Hib
meningitis, we considered complications seen within the
first year. The probability of hearing loss, deafness, seiz-
ure disorders, and cerebral palsy was considered 12.5%,
3.2%, 5%, and 3.5% respectively according to 2 existing
meta- analyses and a domestic study [22–24]. The effi-
cacy of the Hib vaccine after 3 doses against confirmed
invasive Hib diseases, meningitis, and pneumonia was
considered 93%, 88%, and 67%, respectively [25].
Sensitivity analysis
In order to minimize model uncertainty, a sensitivity
analysis was performed with alternative scenarios. In the
basic scenario, we considered that the cost of the vac-
cines and treatment of Hib diseases would be constant
during 5 years and the vaccine effectiveness would be
93%, 88%, and 67% against confirmed invasive Hib dis-
eases, meningitis, and pneumonia, respectively based on
a meta-analysis [25].
In the second scenario, we assumed that the cost of the
Pentavalent vaccine would increase (based on information
obtained from Iran Food and Drug Administration
(IFDA)) during 5 years, the treatment costs would in-
crease by 12% annually (the median increase in the
cost of hospital records in the second year). The vac-
cine effectiveness was assumed the same as the basic
scenario.
In the third scenario, we assumed that the cost of vac-
cination and the cost of treatment would increase during
5 years and the vaccine effectiveness would be 93%
against all Hib diseases. In the fourth scenario, we as-
sumed that the costs would increase during 5 years, the
vaccine effectiveness was considered the same as the
basic scenario, but the vaccine coverage was assumed to
be 100%.
Results
Table 1 shows what information was used to estimate
the costs of vaccination. In the previous schedule, 3
doses of the DTP vaccine were administered at 2, 4, and
6 months of age and the hepatitis B vaccine was
administered at birth and at 2 and 6 months of age.
Therefore, the Pentavalent vaccine replaced 3 doses of
the DTP vaccine and 2 doses of the hepatitis B vaccine
but we still have the hepatitis B vaccine at birth. Based
on the information from the Statistical center of Iran, to
estimate the rural and urban population of Iran, we as-
sumed that 77% of the annual cohort birth was in urban
districts and 23% was in rural districts of the country.
Our first cohort was 1,534,362 children of whom
1,181,458 were in urban and 352,903 were in rural dis-
tricts. The vaccination coverage for the Pentavalent sin-
gle dose, Pentavalent multi dose, hepatitis B, and DTP
was 96.47%, 96.54%, 96.2%, and 96.51%, respectively
[16]. The cost of fully immunizing a child including the
wastage rate was $8.73 for the Pentavalent single dose,
$7.8 for the Pentavalent multi dose, $1.17 for the hepa-
titis B, and $1.14 for the DTP vaccine.
The vaccination cost of previous immunization sched-
ule and the present schedule are shown in Table 2. The
total cost of vaccination during 5 years was $18,060,463
in the previous program and $67,774,786 in the present
program, so inclusion of the Pentavalent vaccine in-
creased the vaccination cost by about $49 million.
Table 3 shows the estimated treatment costs of Hib
diseases in children less than 5 years of age obtained
from hospital records and expert opinions.
Table 4 shows the estimated Hib disease cases before
and after the inclusion of the Pentavalent vaccine in the
childhood immunization schedule in 5 years. The
Pentavalent vaccine would approximately prevent 3010
cases of meningitis, 11458 cases of pneumonia, and 114
cases of septicemia during 5 years.
Based on the estimated number of patients and the
cost of treatment per patient, the overall cost of treating
patients was calculated. Before the inclusion of the
Pentavalent vaccine, the total treatment cost of Hib dis-
eases during 5 years was $8,379,415 which reduced to
$2,098,027 afterwards. Therefore, the financial saving
would be about $6 million.
As Table 5 shows, the cost of new vaccination program
was much higher for the government. In the first year, in
the previous schedule, the cost of vaccination was esti-
mated to be about $3 million but the new vaccination
program cost about $12 million (approximately 4 times
more). The same also applied in following years. On the
other hand, the inclusion of this vaccine saved approxi-
mately $6 million in healthcare costs over 5 years. Dur-
ing 5 years of immunization, the incremental cost was
$43,432,934, from $7,897,693 in the first year to
$9,714,167 in the fifth year.
Sensitivity analysis
As shown in Table 6, all scenarios showed that the
inclusion of the Pentavalent vaccine in the national
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immunization schedule of Iran increased the financial
burden on the government. During 5 years, the total net
budget impact results ranged from + $43 million in the
basic scenario to + $50 million in the fourth scenario,
assuming a vaccination coverage rate of 100% in both
comparative arms. The total net budget impact was +
$48 million in the second scenario where the cost of
vaccination and disease care increased during 5 years,
which is closer to reality, and + $46 millions in the third
scenario with more effective vaccines.
Discussion
The present study was the first BIA for vaccines in Iran
with the aim of evaluating the financial consequences of
adding the Pentavalent vaccine (DTP-HB-HIB) to the
national immunization schedule. Separate DTP and
hepatitis B vaccines were replaced by the Pentavalent in
the national immunization schedule. We measured the
treatment costs of Hib diseases (meningitis, pneumonia,
and septicemia) and also the costs of acute meningitis
sequelae (seizure disorder, hearing problems, deafness,
and cerebral palsy). The study found that the average
per case treatment cost of meningitis, pneumonia, and
septicemia, the main manifestations of Hib, was $693,
$387, and $719 respectively. Moreover, considering the
acute and permanent sequelae, meningitis was the costli-
est Hib disease. Using hospital records as well as the ex-
perts in calculating costs, can be seen as an advantage in
our study.
The total cost of vaccination during 5 years was
$18,060,463 in the previous program and $67,774,786 in
the present program, so inclusion of the Pentavalent vac-
cine increased the vaccination cost by about $49 million
but saved approximately $6 million in the healthcare
costs due to reduction of disease cases and treatment
costs.
Scenario analyses were developed considering uncer-
tainties regarding vaccine effectiveness, cost of the dis-
eases and vaccine, and vaccination coverage. The net
budget impact during 5 years was + $43 million in the
basic scenario, +$48 million in the second scenario in
which the treatment costs and vaccine cost were as-
sumed to increase during 5 years, +$46 million in the
third scenario in which the costs were assumed to in-
crease during 5 years and the vaccine was assumed to be
more effective, and + $50 million in the last scenario
with a 100% vaccination coverage. As the results
showed, the difference between the best and the worst
scenario was 16%. The sensitivity analysis showed that
the model results were robust to changes in the parame-
ters analyzed and the uncertainties in this study did not
have significant effects on the results. The four scenarios
analyzed in our model suggest that after 5 years, adding
the Pentavalent vaccine to the national immunization
schedule would impose a significant burden on the gov-
ernmental healthcare budget.
The most important reason for this financial burden
is the price of the vaccine. Before including the
Pentavalent vaccine, the program offered universal
immunization against tuberculosis, poliomyelitis, diph-
theria, tetanus, pertussis, hepatitis B, measles, mumps,
Table 2 Vaccination costs including vaccine and syringe costs













Year 1 2,873,626 3,221,945 11,881,606 12,090,866
Year 2 3,017,308 3,383,042 12,475,686 12,695,409
Year 3 3,189,294 3,575,875 13,186,800 13,419,047
Year 4 3,393,409 3,804,731 14,030,756 14,277,866
Year 5 3,634,341 4,074,867 15,026,939 15,291,595
Total 16,107,980 18,060,463 66,601,789 67,774,786
DTP Diphteria, Tetanus, Pertusis, HB Hepatitis B, USD United States Dollars
Table 3 Estimated Hib disease treatment costs in children less
than 5 years
Hib diseases Mean cost (USD) SD (USD) 95% CI
Meningitis 693 393 (401–984)
Pneumonia 387 162 (257–517)
Septicemia 719 488 (380–1057)
Seizure disorder 570 98 (433–707)
2 years outpatient seizure
disordera
418 NA NA
Hearing lossa 42 NA NA
Deafnessa 1773 NA NA
Cerebral palsy 554 230 (294–814)
Hib Haemophilus influenzae type b, NA Not Applicable, USD United States
Dollars; a: Based on expert opinions
Table 4 Estimated Hib disease cases before and after inclusion
of Pentavalent vaccine in the childhood immunization schedule
in 5 years






Meningitis 3420 410 3010
Pneumonia 17100 5642 11458
Septicemia 1197 83 1114
Seizure disorder 120 14 106
Hearing loss 427 53 374
Deafness 109 13 96
Cerebral palsy 171 21 150
Hib Haemophilus influenzae type b
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and rubella [9]. The replacement of the domestic
vaccines (DTP and hepatitis B) with expensive
imported vaccines (Pentavalent) increased the net
budget impact, so regarding the history and potential
for vaccine production in the country, one solution to
reduce this financial burden in the long term is to
support domestic production by investment in this
field, renewal of the infrastructures, and implementa-
tion of new technologies.
In the Iranian healthcare system, the Ministry of
Health is responsible for providing free vaccines for all
children in the country. Every year, the Management and
Planning Organization of Iran approves the budget
needed for vaccine supplies. The purchase and procure-
ment of vaccines for national programs is the responsi-
bility of the IFDA. The IFDA estimates the maximum
amount of funding every year. According to the existing
documents at IFDA, in the second year of including the
Pentavalent vaccine in the program, by assuming a 100%
vaccination coverage rate, the IFDA estimated the max-
imum budget needed for purchasing Pentavalent vaccine
would be $14 million which is similar to our findings
($13,800,000). However, BIA has never been conducted
by the Iranian MOH. The results of this study can be
Table 5 Budget impact results
Annual cost outcomes Year 1 Year 2 Year 3 Year 4 Year 5 Total (5 years results)
Previous vaccination program (DTP + HB)
Vaccination costs (USD) 3,221,945 3,383,042 3,575,875 3,804,731 4,074,867 18,060,463
Hib disease care costs (USD) 1,295,624 1,522,358 1,697073 1,859,932 2,004,425 8,379,415
Total costs (USD) 4,517,569 4,905,401 5,272,949 5,664,664 6,079,293 26,439,878
New vaccination program (Pentavalent)
Vaccination costs (USD) 12,090,866 12,695,409 13,419,047 14,277,861 15,291,595 67,774,786
Hib disease care costs (USD) 324,396 381,166 424,911 465,687 501,865 2,098,027
Total costs (USD) 12,415,263 13,076,575 13,843,959 14,743,554 15,793,461 69,872,813
Budget impact (BI)
Vaccine BI (USD) 8,868,921 9,312,367 9,843,172 10,473,135 11,216,727 49,714,322
Hib disease care BI (USD) -971,227 -1,141,192 -1,272,162 -1,394,245 -1,502,559 -6,281,387
Net BI (USD) 7,897,693 8,171,174 8,571,009 9,078,889 9,714,167 43,432,934
DTP Diphteria, Tetanus, Pertusis, HB Hepatitis B, USD United States Dollars, Hib Haemophilus influenzae type b
Table 6 Sensitivity analysis results
Year 1 Year 2 Year 3 Year 4 Year 5 Total (5 years results)
Base scenario
Vaccine BI (USD) 8,868,921 9,312,367 9,843,172 10,473,135 11,216,727 49,714,322
Hib disease care BI (USD) -971,227 -1,141,192 -1,272,162 -1,394,245 -1,502,559 -6,281,387
Net BI (USD) 7,897,693 8,171,174 8,571,009 9,078,889 9,714,167 43,432,934
Second scenario
Vaccine BI (USD) 8,868,921 9,940,023 11,269,731 12,577,727 14,222,115 56,878,518
Hib disease care BI (USD) -971,227 -1,278,135 -1,595,800 -1,958,814 -2,364,306 -8,168,285
Net BI (USD) 7,897,693 8,661,887 9,673,930 10,618,913 11,857,808 48,710,233
Third scenario
Vaccine BI (USD) 8,868,921 9,940,023 11,269,731 12,577,727 14,222,115 56,878,518
Hib disease care BI (USD) -1,204,777 -1,585,487 -1,979,541 -2,429,848 -2,932,849 -10,132,504
Net BI (USD) 7,664,143 8,354,535 9,290,189 10,147,879 11,289,266 46,746,014
Fourth scenario
Vaccine BI (USD) 9,183,753 10,293,241 11,670,517 13,025,331 14,728,569 58,901,414
Hib disease care BI (USD) -971,227 -1,278,135 -1,595,800 -1,958,814 -2,364,306 -8,168,285
Net BI (USD) 8,212,525 9,015,105 10,074,716 11,066,517 12,364,262 50,733,128
BI Budget Impact, USD United States Dollars
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used for budget planning, especially by the Management
and Planning Organization of Iran.
Based on domestic studies on the epidemiology of Hib
meningitis and the cost-effectiveness of the Hib vaccine
in Iran (previously described), WHO recommendations,
availability of the vaccine in other countries, and the effi-
cacy of the vaccine, the NITAG approved Hib vaccin-
ation to be included in the EPI. However, some issues
like financing problems, different priorities of the
Ministry of Health, plans to produce the Hib vaccine in
the country, and finding a proper importer caused a
delay in the inclusion of the vaccine in the immunization
schedule [9]. Based on WHO reports, Iran was one of
the last countries to include the Hib vaccine in its na-
tional vaccination program.
In other countries, the Hib vaccine was introduced
sooner and many cost-effectiveness studies were done
about Hib vaccination which all concluded that this
intervention was cost-effective in the context of their
countries like India, Indonesia, Kenya, and Russia
[26–29]. However, for very new vaccines like rotavirus
vaccine and pneumococcal vaccine, BIA studies have
been done in different countries like Spain [30, 31],
Germany [32], and New Zealand [33]. The BIA is a
new decision making tool and since the Hib vaccine
is almost an old vaccine, no BIA study has evaluated
it. Two BIA studies have been conducted for including the
rotavirus vaccine in the childhood immunization schedule
in Spain and New Zealand. The Spanish study estimated
that the economic impact of introducing universal infant
rotavirus vaccination in Spain would be €10.43 million per
year, from the perspective of the Spanish National Health
System [30]. In New Zealand, the budget impact in
the 5th year of an immunization program with a
Pentavalent rotavirus vaccine was estimated $4.78 mil-
lion from the perspective of the government [33].
As this study was the first BIA on vaccines in Iran, its
methodology may be useful for future BIA studies on
other new vaccines because all the pharmaceutical com-
panies have to submit an economic evaluation profile
(including the cost-effectiveness study and BIA) for their
new products to the IFDA from 2014, and the vaccines
are not an exception [34].
Our study has some limitations. To conduct accurate,
useful, and attributable economic evaluation studies like
BIA, reliable information about the disease burden is re-
quired. Lack of disease burden studies and reliable infor-
mation on the incidence of Hib diseases and disease
cases were the main limitations of this study. One of the
reasons for the lack of the above information is that
when a patient is hospitalized with meningitis symp-
toms, antibiotic therapy starts immediately so the cul-
ture of the specimens taken from the patient will be
negative. On the other hand, because the PCR method is
not available in all hospitals, it is difficult to identify the
pathogen.
The second limitation was the lack of vaccine efficacy
data in Iran. We extracted the vaccine efficacy data from
a meta-analysis [25]. However, we can not predict
whether the imported Pentavalent vaccine will have the
same efficacy in Iran, and more data need to be collected
on the effectiveness and safety of the Pentavalent vaccine
in Iran.
Another point is that in measuring the treatment costs
of complications due to meningitis, we considered the
problems which can be seen in the first year (acute
complications). However, permanent sequelae, like men-
tal retardation, cause productivity loss and health costs
in the long term, so the inclusion of the Hib vaccine will
save some costs from the perspective of the society.
To respond to domestic demands and keep pace with
other countries, inclusion of new and expensive vaccines
in the NIP of Iran is inevitable. Despite the limitations
mentioned above, the results suggest an increase in the
government expenditure on new vaccines. However, it
should be noted that the BIA is one of the decision-
making tools and other reasons may affect the policy
makers’ decisions on the arrival of the new vaccines.
One of the most important reasons can be the value of
the children’s lives as the productive forces in the future.
It is suggested to conduct a study to investigate the rea-
sons affecting the decision-makers’ decision on the ar-
rival of new vaccines.
Conclusion
In conclusion, according to our model and estimates,
the results showed that inclusion of the Pentavalent vac-
cine (HIB-HBV-DTP) in the national immunization
schedule of Iran causes a significant impact on the
healthcare budget and increases the financial burden on
the government.
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